The present invention relates to nano-liposome carrier compositions that encapsulate a hybrid of a Cas9 protein and a guide RNA and methods of making and using the same. The nano-liposome carrier compositions have an excellent effect of suppressing expression of target DNA, and thus pharmaceutical compositions including the nano-liposome carrier compositions can be used for treating diseases such as diabetes.

The present invention provides a functionalized mRNA including mRNA and double-stranded RNA including at least one RNA oligomer hybridized with mRNA. Functionalized mRNA is provided according to this configuration.

The present disclosure relates to isolated, therapeutic agent delivery platforms and, more particularly, to engineered, fusogenic particles and related methods for targeted delivery of therapeutic agents to cells. One aspect of the present disclosure relates to an isolated, fusogenic particle including a lipid envelope associated with at least one targeting protein, and a therapeutic agent contained within the fusogenic particle. The at least one targeting protein can be a viral fusion protein or a cognate receptor of a viral fusion protein. Other aspects of the present disclosure relate to in vivo and in vitro methods for delivering therapeutic agents to cells using the fusogenic particles.

In an embodiment, a drug delivery system and method of use thereof to treat inflammation and bacterial pathogens including multi-drug resistant pathogens, such as MDR-Pseudomonas aeruginosa, or reactive oxygen species in a subject is provided. In some embodiments, the drug delivery system includes a polymeric material, an excepient, an antioxidant agent, and an anti-inflammatory and antimicrobial agent. In some embodiments, the anti-inflammatory and antimicrobial agent is a salt of an anti-inflammatory agent and an antimicrobial agent formulated to provide a combination of antimicrobial and anti-inflammatory action from a single molecule. In some embodiments, the combined anti-inflammatory and antimicrobial agent is a silver salt of ibuprofen. In other embodiments, the combined anti-inflammatory and antimicrobial agent is unmodified, native ibuprofen.

A method of manufacturing an immunogenic composition forming a vaccine, the method including providing a dried nanoparticle adjuvant, wherein the nanoparticle adjuvant includes a plurality of nanoparticles, and each nanoparticle comprises a lipid layer exterior including a plurality of lipids, cholesterol, and a primary alkyl amine including an amino group head and at least a carbon tail, providing a dried antigen, combining the dried antigen with the dried nanoparticle adjuvant, and reconstituting the combined dried antigen and dried nanoparticle adjuvant.

An isolated or a synthetic targeting peptide comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 8 is disclosed. The targeting peptide may be conjugated to a component selected from the group consisting of polymeric micelles, lipoprotein-based drug carriers, nanoparticle drug carriers, a chemotherapeutic agent, a micelle, a liposome, dendrimers, a polymer, a lipid, an oligonucleotide, a peptide, a polypeptide, a protein, a prostate cancer cell, a stem cell, and an imaging agent. Also disclosed are a kit for imaging and detecting the presence of prostate cancer cells in vivo or in vitro, and a composition for treating prostate cancer, inhibiting prostate cancer cell growth, inducing prostate cancer cell cytotoxicity, and/or increasing the survival rate in a prostate cancer patient.

The present disclosure relates to specific delivery of a lipid-peptide conjugate to immune cells ex vivo or in vivo for decreasing or increasing an immune response against therapeutically relevant antigens. The lipid-peptide-antigen is comprised of a peptide, a lipid, and a functional group that is degraded in a biological environment within cells to release the peptide for MHC presentation and provides a more efficient presentation of antigen epitopes by antigen presenting cells than peptide epitopes alone.

Defined multi-conjugate oligonucleotides can have predetermined sizes and compositions. For example, in various embodiment, defined multi-conjugate oligonucleotides can have advantageous properties, for example in the form of defined multi-conjugate siRNA (i.e., including two, three or more siRNA) having enhanced intracellular delivery and/or multi-gene silencing effects. In various embodiment, the defined multi-conjugate oligonucleotides can be synthesized via new synthetic intermediates and methods. The defined multi-conjugate oligonucleotides can be used, for example, in reducing gene expression, biological research, treating or preventing medical conditions, or to produce new or altered phenotypes in cells or organisms.

Engineered nano-liposomes (immuno-nanoliposomes) and their preparation process, for use as a treatment in atherosclerosis therapy, containing therapeutic mono-clonal antibodies and having poly-anions and/or poly-cations on the external surface, to which monoclonal antibodies specific for atheromatous plaques capable of guiding said nano-liposomes are grafted.

The disclosure relates generally to polyglutamated antifolates, formulations containing liposomes filled with alpha or D-gamma polyglutamated antifolates, methods of making the polyglutamated antifolates and liposome containing formulations, and methods of using polyglutamated antifolates and liposome containing formulations to treat hyerproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., an autoimmune disease such as rheumatoid arthritis).